SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported) July 14, 1998

                                   ENZON, INC.
             (Exact name of registrant as specified in its charter)

        Delaware                      0-12957                     22-237286
(State or other jurisdiction        (Commission                 (IRS Employer
    of incorporation)                File Number)               Identification)


                20 Kingsbridge Road, Piscataway, New Jersey      08854
               (Address of principal executive offices)        (Zip Code)


        Registrant's telephone number, including area code (732) 980-4500


________________________________________________________________________________
          (Former name or former address, if changed since last report)





Item 5. Other Events

Company Completes $19 Million Private Placement

     Enzon,  Inc. (the  "Company")  announced the  completion of its  previously
announced private placement. Under the private placement agreements,  which were
signed on June 25, 1998, the Company sold 3,983,000  shares of common stock to a
small group of investors resulting in gross proceeds of $18,919,250. The private
placement was managed by Warburg Dillon Read LLC.

     The net proceeds of the private placement of approximately $17,600,000 will
be used for general corporate  purposes,  including  further  development of the
Company's second and third generation PEG  (polyethylene  glycol) products in an
effort to create more value  before such  products are licensed out to strategic
partners.  Proceeds  will also be used to  develop a number of  additional  high
potential PEG and Single-Chain  Antigen-Binding  (SCA(R)) Protein compounds. The
proceeds  from this  private  placement  along with the  Company's  current cash
reserves  should  be  sufficient  to  meet  the  Company's  future  capital  and
operational  requirements for the foreseeable future, based on currently planned
research and development activities and related costs.

     The  financing  provides  the Company  with  resources  to  accelerate  its
existing  programs and bring in additional  high potential PEG and SCA products.
The Company  expects that the financing will eliminate the Company's  dependence
on the capital markets for the funding of currently  planned  operations for the
foreseeable future.


     Except for the historical  information herein, the matters discussed herein
include  forward-looking  statements  that may  involve  a number  of risks  and
uncertainties.  Actual  results  may vary  significantly  based upon a number of
factors which are described in the Company's Form 10-K, Form 10-Q's and Form 8-K
on file with the SEC,  including  without  limitation,  risks in  obtaining  and
maintaining  regulatory approval for expanded indications,  market acceptance of
and continuing  demand for the Company's  products and the impact of competitive
products and pricing.





                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Dated: July 17, 1998


                                                        ENZON, INC.      
                                                       (Registrant)

                                             By:  /S/ KENNETH J. ZUERBLIS
                                                  ----------------------------
                                                  Kenneth J. Zuerblis
                                                  Vice President, Finance
                                                  and Chief Financial Officer